Suntrust Banks’s TherapeuticsMD TXMD Stock Holding History

Suntrust Banks’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-600	Closed	-$146K	–	1355
2019 Q1	$146K	Buy	+600	New	+$159K	﹤0.01%	1252
2018 Q1	–	Sell	-814	Closed	-$246K	–	1345
2017 Q4	$246K	Hold	814	–	–	﹤0.01%	1114
2017 Q3	$215K	Hold	814	–	–	﹤0.01%	1173
2017 Q2	$215K	Sell	814 -100	-11%	-$25K	﹤0.01%	1174
2017 Q1	$329K	Buy	914 +514	+129%	+$159K	﹤0.01%	993
2016 Q4	$115K	Hold	400	–	–	﹤0.01%	1534
2016 Q3	$136K	Hold	400	–	–	﹤0.01%	1490
2016 Q2	$170K	Hold	400	–	–	﹤0.01%	1413
2016 Q1	$128K	Buy	+400	New	+$136K	﹤0.01%	1407
2015 Q4	–	Sell	-400	Closed	-$117K	–	1505
2015 Q3	$117K	Buy	+400	New	+$142K	﹤0.01%	1233
2015 Q1	–	Sell	-400	Closed	-$89K	–	1261
2014 Q4	$89K	Hold	400	–	–	﹤0.01%	1162
2014 Q3	$92K	Buy	400 +100	+33%	+$25.2K	﹤0.01%	1360
2014 Q2	$66K	Buy	+300	New	+$66.8K	﹤0.01%	1395

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Suntrust Banks's TXMD Position: Q2 2019 in Review

Suntrust Banks sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 600 shares — an estimated $146K sold.

Suntrust Banks first reported a position in TXMD in Q2 2014 and held it in 13 quarters. The position peaked at $329K in Q1 2017. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

Suntrust Banks reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
Suntrust Banks sold 600 TherapeuticsMD shares in Q2 2019, an estimated $146K.
Suntrust Banks first reported a position in TherapeuticsMD in Q2 2014 and held it in 13 quarters.
Suntrust Banks's TherapeuticsMD position peaked at $329K in Q1 2017.
148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Suntrust Banks's 13F filing for Q2 2019, filed 6 Aug 2019.